LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 108 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $18,600 | +28.2% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $14,508 | +3.6% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $14,000 | -30.0% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $20,000 | +5.3% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $19,000 | -36.7% | 12,400 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $30,000 | -36.2% | 12,400 | -32.6% | 0.00% | -33.3% |
| Q3 2021 | $47,000 | -29.9% | 18,400 | -21.2% | 0.00% | -40.0% |
| Q2 2021 | $67,000 | +45.7% | 23,360 | +18.8% | 0.01% | +25.0% |
| Q1 2021 | $46,000 | +70.4% | 19,670 | +24.9% | 0.00% | +100.0% |
| Q4 2020 | $27,000 | +92.9% | 15,750 | +6.8% | 0.00% | +100.0% |
| Q3 2020 | $14,000 | 0.0% | 14,750 | -8.7% | 0.00% | 0.0% |
| Q2 2020 | $14,000 | -6.7% | 16,150 | -19.9% | 0.00% | -50.0% |
| Q1 2020 | $15,000 | -16.7% | 20,150 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $18,000 | -47.1% | 20,150 | -42.7% | 0.00% | -50.0% |
| Q3 2019 | $34,000 | – | 35,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
| Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
| Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
| Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
| DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
| Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
| MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
| Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |